Journal
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
Volume 13, Issue 4, Pages 649-651Publisher
WILEY
DOI: 10.1111/cts.12753
Keywords
-
Categories
Ask authors/readers for more resources
Ranitidine has been the topic of recent media reports. Current findings, confirmed by the US Food and Drug Administration, indicate that some ranitidine products contain a substance that may be carcinogenic. Providers and patients require additional information on the risks of continuing therapy vs. the benefits of the medication. This article comments on what is currently known about the evolving situation of elevated N-nitrosodimethylamine levels in ranitidine and the limits of the existing information to assess best practices.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available